ORBIMED ADVISORS LLC

Position in NKTR — Nektar Therapeutics

CIK 1055951 New York, NY

Back to NKTR Full portfolio

Position in NKTR

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$32,485,804

+$12,699,554 QoQ

Shares Held

465,346

+69.2% QoQ

Ownership

1.36%

of shares outstanding

% of Portfolio

0.64%

of 13F equity value

Holder Rank

#18

of 239 holders

Holding Since

Mar 2023

4 quarters on record

Voting authority Sole 53% Shared 0% None 47%

Common Shares in NKTR Over Time

Shares Held

Position Value (USD)

Derivatives in NKTR

reported options exposure · as of Jun 30, 2023

CallValue

$298,700

CallShares

34,333

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ORBIMED ADVISORS LLC holds $3,639,640,835 across 90 Biotechnology names. NKTR ranks #32 (0.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	EWTX	Edgewise Therapeutics, Inc.	15,518,492	$630,516,329
2	ELVN	Enliven Therapeutics, Inc.	6,776,632	$343,914,074
3	MBX	MBX Biosciences, Inc.	3,428,736	$189,266,227
4	GPCR	Structure Therapeutics Inc.	2,209,400	$118,578,498
5	SION	Sionna Therapeutics, Inc.	2,555,877	$112,433,029
6	CRVS	Corvus Pharmaceuticals, Inc.	7,165,006	$107,045,189
7	AVBP	ArriVent BioPharma, Inc.	3,027,328	$105,169,374
8	ARGX	Argenx SE	92,880	$86,171,277

All Filings in NKTR

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$32,485,804	465,346	+69.2%	Shares	Defined	2026-08-14
2026-03-31	$19,786,250	275,000	-73.4%	Shares	Defined	2026-05-15
2023-06-30	$298,700	515,000	-5.5%	Call	Defined	2023-08-14
2023-03-31	$381,500	545,000	—	Call	Defined	2023-05-15
2023-03-31	$723,841	1,034,059	—	Shares	Defined	2023-05-15
No filing history on record for this holder in this stock.